Canaccord Genuity
Canaccord Genuity is the global capital markets division of Canaccord Financial Inc. (CF : TSX | CF. : AIM), offering institutional and corporate clients idea-driven investment banking, research, sales and trading services.
The companies has operations in 24 cities worldwide and the ability to list companies on 10 stock exchanges.
-
Atara Biotherapeutics to Present at the Canaccord Genuity 42nd Annual Growth Conference
-
ATARA Biotherapeutics (ATRA) Prices 5.102M Share Common Offering at $24.50/Sh
-
Atara Biotherapeutics Announces Pricing of $175.0 Million Public Offering
-
Atara Biotherapeutics Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
ATARA Biotherapeutics (ATRA) Prices 12.63M Share Common Offering at $11.32/Sh
-
Atara Biotherapeutics Announces Pricing of $175.5 Million Public Offering
-
ATARA Biotherapeutics (ATRA) Announces Proposed Common Share & Pre-Funded Warrants Offering
-
Atara Biotherapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants
-
ATARA Biotherapeutics (ATRA) Prices 6.87M Share Common Offering at $15.28/Sh
-
Atara Biotherapeutics Announces Pricing of $150.0 Million Public Offering
-
Atara Biotherapeutics Announces Pricing of $150.0 Million Public Offering
-
ATARA Biotherapeutics (ATRA) Announces Proposed $125M Share Common Offering
-
Atara Biotherapeutics Announces Proposed Offering of Common Stock
-
Atara Biotherapeutics Announces Proposed Offering of Common Stock
-
Canaccord Genuity Reiterates Buy Rating on Atara Biotherapeutics (ATRA)
-
Atara Biotherapeutics (ATRA) KOL Call Suggests Single Arm Trial For Approval - Canaccord
-
Atara Biotherapeutics to Participate in the Canaccord Genuity 38th Annual Growth Conference
-
Atara Biotherapeutics to Participate in the Canaccord Genuity 38th Annual Growth Conference
-
ATARA Biotherapeutics (ATRA) Prices 4.286M Common Share Offering at $35/Sh
-
Atara Biotherapeutics Announces Pricing of Public Offering of Common Stock
-
Atara Biotherapeutics Announces Pricing of Public Offering of Common Stock
-
Canaccord Genuity Remains Bullish on ATARA Biotherapeutics (ATRA)
-
Atara Biotherapeutics (ATRA) PT Raised to $70 at Canaccord Genuity, 'see strong outcome for Phase 3 data based on prior studies'
-
ATARA Biotherapeutics (ATRA) Prices 7M Share Common Offering at $18.25/Sh
-
Atara Biotherapeutics Announces Pricing of Public Offering of Common Stock
-
Atara Biotherapeutics Announces Pricing of Public Offering of Common Stock
-
Atara Biotherapeutics to Present at the Canaccord Genuity 37th Annual Growth Conference
-
Atara Bio to Present at the Canaccord Genuity 36th Annual Growth Conference
-
Atara Bio Announces Participation in Two Upcoming Investor Conferences
-
Canaccord Genuity Remains Bullish on ATARA Biotherapeutics (ATRA) Despite Negative Phase 3 Data
-
Canaccord Genuity Starts Atara Biotherapeutics (ATRA) at Buy
-
Atara Biotherapeutics Announces Second Quarter 2015 Results
-
Atara Bio Announces Closing of Underwritten Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
-
ATARA Biotherapeutics (ATRA) Prices 3.46M Common Stock Offeirng at $52/Share
-
Atara Bio Announces Pricing of Its $180.0 Million Offering of Common Stock
-
Atara Biotherapeutics (ATRA) Announces $125M Common Stock Offering
-
Atara Bio Announces Proposed Offering of Common Stock

